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BriefDefinitive Report
Studies of the molecular systems determined by genes that map in the major
histocompatibility complex (MHC) have led to the recognition of an alloantigenic
system preferentially expressed on B lymphocytes (1). This B-cell system has extensive
biological and chemical homologies with the I-region antigens of the murine histo-
compatibility system and has been termed Ia-like or simply Ia. These Ia alloantigens
were recognized with alloantibodies that developed as a result of immunization with
paternal antigens during pregnancy, or in the sera of renal transplant recipients who
became immunized against nonmatching antigens present on the homograft. These
human Ia determinants are highly polymorphic, with certain alloantigenic specificities
relating closely to HLA-D alleles defined by the mixed lymphocyte culture reaction
(2) ; for this reason, particular Ia phenotypes were designated HLA-DR (3) .
The relevance of the B-cell alloantigens to the immunogenetics of disease was first
shown for multiple sclerosis (4), where a very high percentage of patients reacted with
a particular serum with a specificity related to what is now termed DRw2. These
studies suggested that an important application of the B-cell alloantisera might be
their potential for the recognition of MHC-related disease, even in rheumatoid
arthritis (RA) and systemic lupus erythematosus (SLE) where no clear MHC associ-
ations had been evident by classical HLA-A and B locus typing.
The preliminary observation that one B-cell alloantiserum reacted with a high
percentage of patients with RA (5), suggested that patients with SLE would also show
a relationship to alleles of the MHC, because these two diseases while clinically
distinct, are nonetheless thought to be related. In the present study, further evidence
for the value of Ia alloantigen typing was obtained in patients with RA or SLE ;
however, markedly contrasting MHC relationships were observed for these two
diseases, suggesting that they have very different etiologies.
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TABLE I
Contrasting B-Cell Alloantigen Profiles in Patients with Rheumatoid Arthritis and Systemic Lupus
Erythematosus
1729
Materials and Methods
Patient Selection and Cell Preparation. Mononuclear cells were isolated by Ficoll-Hypaque
centrifugation from blood samples obtained from normal volunteers and from patients meeting
the American Rheumatism Association criteria for seropositive RA or SLE. T cells were
removed by depletion of the lymphocytes forming rosettes with sheep erythrocytes previously
treated with neuraminidase as described elsewhere (6) . The enriched preparations of B cells
were incubated overnight in medium RPMI-1640 supplemented with 10% fetal calf serum in
plastic T flasks (BioQuest, BBL & Falcon Products, Becton, Dickinson, & Co., Cockeysville,
Md.) to remove adherent cells. B-cell lymphoid lines were maintained in medium RPMI-1640
supplemented with 10% fetal calf serum. Included among the 40 cell lines used for reference
purposes were those derived from individuals who were homozygous for mixed lymphocyte
culture specificities HLA-DW1, DW2, DW3, DW4, DW5, DW6, DW7, and DW 10.
Preparation of Ia Antisera Typing Panel.
￿
Over 200 sera from multiparous women and renal
transplant recipients characterized as having B-cell alloantibodies (7) were absorbed twice,
volume-for volume, with T-lymphocytes and packed pooled platelets, for 1 h at 4°C. The
resulting sera were free of anti-HLA A, B, and C activity when retested on peripheral blood T
lymphocytes.
B-Cell Alloantigen Assay.
￿
A modified Amos two-stage microcytotoxicity assay was performed
on the purified B cells and reference B-cell lines, in accord with standard methods (8). In the
first step, the cell-serum mixture was incubated for 20 min at 37°C. Prescreened rabbit serum
found to be free of naturally occurring cytotoxic activity against human lymphocytes was
added as a source of complement, the mixture incubated for 30 min at 37 °C. Each reaction
was performed in duplicate, and was considered positive if 50% or greater number of cells
above control stained with trypan blue dye. Relative risk, calculated according to Woolf (9),
estimates the risk of developing the disease if the alloantigen is present. If no association exists,
the relative risk = 1.0.
Results
Table I illustrates contrasting B-cell alloantigen profiles in patients with RA and
SLE detected by the selected reagent alloantisera. The most significant association in
patients with RA was the high frequency of alloantigens detected by serum 1283.
This serum reacted with 80% of patients with RA (relative risk = 9.1), 31% of
normals, but only 12% of patients with SLE. Two alloantisera 259 and 1038 not
illustrated in the Table gave essentially the same pattern of reaction as serum 1283.
An additional two antisera 924 and 191 which were very similar to each other gave
reactions that partially resembled the pattern of the previous three alloantisera in
Reagent
HLA-DR,
Specificity (
no-m40
)
Frequency
Rheumatoid arthritis
(n = 44)
Frequency XU RR,,
Systemic
Frequency
lupus erythematosus
(n = 24)
Xz RR
.
7Am 1 31 9 4.9* 0.2 30 0.0 1.0
1239 2 25 13 1.2 0.5 50 3.9* 3.0
1066 2 + 3 34 34 0.0 1.0 75 9.4* 5.7
1033 3 20 14 0.2 0.6 54 6.5* 4.7
1283 4 x 7 x 10 31 80 16.9* 9.1 12 1 .7 0.3
1995 5 11 4 0.5 0.4 8 0.0 0.7
a = chi square, corrected (Yates).
b - relative risk.
* Statistically significant values: for e> 3.8, P < 0.05; 6.6, P < 0.01 ; 7.9, P< 0.005.1730
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that they reacted with 60% of patients with RA, 22% of normal subjects and only 4%
of patients with SLE, relative risk 0.2. The alloantigen detected by serum 7Am was
detected in only 9% ofpatients with RA but in 31% of the normal control population
as well as in 30% of patients with SLE.
Among patients with SLE, the greatest frequency of reactivity was found with
serum 1066, accounting for 75% of the population (relative risk = 5.7). Serums 1239
and 1033 gave lesser but still significantly increased frequencies of reaction among
patients with SLE. The positive reactions of serum 1066 included those patients with
SLE who were positive with either serum 1239 or 1033. Not illustrated in the Table
are four additional sera that gave nearly identical patterns of reaction to either serum
1239 or serum 1033. Problems were encountered in typing a few of the SLE patients,
presumably due to high concentrations of monocytes in the typing preparations.
These patients were excluded from the study.
Analysis of the reactivity of the reagent sera with a panel of reference B-cell
lymphoblastoid lines derived from individuals homozygous for HLA-D alleles pro-
vided a means of describing the relationship of the alloantigens detected by the sera
to certain known markers of the histocompatibility complex, as shown in the second
column of the Table. Sera 1283, 259, and 1038 reacted with each of four B-cell lines
derived from individuals homozygous for DW4, all three from individuals homozygous
for DW7, and all three from individuals homozygous for DW10. Sera 924 and 191
not illustrated in the Table reacted with all cell lines derived from individuals who
were either DW4 or DW 10 but not with lines derived from individuals who had any
other D locus specificities including DW7. Serum 1066 reacted with each of five cell
lines from individuals who were homozygous for DW2 and with lines from five
individuals homozygous for DW3. Serum 1239 reacted only with the DW2 cell lines
and serum 1033 reacted only with the lines derived from the DW3 positive individuals.
Sera 7Am and 1995 reacted respectively with cell lines derived from DW 1 or DW5
positive individuals.
Absorption experiments with the prototype alloantisera, 1066 and 1283, gave
different results. Absorption of serum 1066 with B-cell lines derived from individuals
positive for either DW2 or DW3 left intact an alloantibody reacting with the cell line
of the other specificity. For this reason, the specificity of serum 1066 was designated
DRw2+3. Absorption of serum 1283 with B-cell lines derived from any individuals
homozygous for either DW4, DW7, or DW 10 removed antibody reactivity against all
three. The specificity defined by this alloantiserum was designated DRw4x7x10.
Discussion
The present study demonstrated distinct B-cell alloantigen profiles in patients with
SLE or RA, two rheumatic diseases frequently considered related. Two alloantisera
were identified that discriminated between the disease groups particularly well. Serum
1066 reacted with 75% of the SLE patients. In contrast, serum 1283 reacted with 80%
of patients with RA, but only 12% of patients with SLE.
Sera in this study were defined by their disease association. This was of some
novelty in that it afforded insights into the nature of genetic associations that might
not otherwise have been as readily apparent. In this context, the relationship of a
particular alloantigen defined by a B-cell alloantiserum to individual alleles of a
single MHC locus, might be of lesser significance than the relationship to an as yetGIBOFSKY ET AL.
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undefined disease susceptibility gene with which it is in linkage disequilibrium. It will
remain for future work to delineate the exact fine specificities of these antisera.
Also of interest is the observation of a low fractional relative risk for a specific
alloantigen in a given patient population. Examples ofthis are the decreased frequency
of the reactivity with allosera 924, 191, and 1283 among patients with SLE, and the
decreased frequency ofthe reactivity ofserum 7AM in patients with RA. This suggests
that although the inheritance of particular alloantigens was associated with suscepti-
bility to certain diseases, the possibility exists that they may also confer resistance to
others.
The use of reference B-cell lines permitted a description of the relationship of the
alloantigens detected by these sera to certain defined markers of the HLA system.
Serum 1066 contained two antibody specificities that in part related to DRw2 and
DRw3. Absorption of this antiserum with B cells homozygous for either specificity
did not remove reactivity against the other, indicating that these two antibodies were
distinct and not cross-reactive. The association between susceptibility to SLE and
DRw2 and DRw3 has also been recognized in another population by Reinartsen et
al. (10) as well as in a preliminary report on the present patients (11). Serum 1283
and the related sera 259 and 1038 detected an alloantigen shared by individuals
positive for either DRw4, DRw7, or DRw10. A lower association between DRw4
alone and susceptibility to RA has been reported by Stastny (12). Absorption of serum
1283 with B cells homozygous for either specificity completely and reciprocally
removed antibody activity against any single one. In this instance, partial analysis
indicated that the serum detected a public specificity which was, in turn, associated
with susceptibility to RA.
Summary
Increasing evidence has been obtained of the special value of la-like B-cell alloan-
tisera for demonstrating disease associations with histocompatibility antigens. This
was particularly evident for the study of the immunogenetics of rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE), two conditions frequently considered
related. The profiles of antigens recognized by the alloantisera in patients from each
disease group was distinctive. Two types of alloantisera were obtained that illustrated
the divergence between the two diseases. One . type showed a higher than normal
incidence in RA but lower than normal in SLE ; the other showed a higher incidence
in SLE. While these sera were not totally defined, evidence was obtained that the
SLE-reactive alloantiserum related to two alleles of the major histocompatibility
complex DRw2 and DRw3, while the RA-reactive alloantiserum related to a common
specificity shared by cells positive for either DRw4, DRw7, or DRw10. The data
indicate that imunogenetic factors are relevant to the development of both RA and
SLE, but that these are distinct for each disease.
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